Phase II trials articles from across Nature Portfolio

In a phase Ib trial, neoadjuvant nivolumab or nivolumab/relatlimab prior to chemoradiotherapy were well tolerated and liquid biopsy analyses show that undetectable ctDNA was associated with longer survival.

In a randomized phase 2 trial comparing anti-PD-1 plus anti-VEGF plus an HDAC inhibitor versus anti-PD-1 plus an HDAC inhibitor in patients with MSS/pMMR colorectal cancer, the triplet combination led to significantly better 18-week progression-free survival.

CAMILLA is a basket trial evaluating cabozantinib plus the ICI durvalumab in chemorefractory gastrointestinal cancer. Here, the authors present the result of the phase II in the colorectal cohort.

Results from a multicenter, randomized phase 2 trial in China show that adjuvant anti-PD-1 therapy in patients with resected hepatocellular carcinoma with microvascular invasion leads to prolonged recurrence-free survival compared to active surveillance.

A flurry of emerging treatment options is transforming the therapeutic landscape of hepatocellular carcinoma; two new studies highlight the complexities and gaps in knowledge, but also hint at a greater understanding of how to apply immunotherapy in early and advanced disease.

The US FDA Accelerated Approval of sotorasib required the sponsor to conduct a randomized trial that compared the safety and efficacy of the approved dose with a lower dose. These results, recently disclosed, have important implications for patients, payers, oncologists and the pharmaceutical industry.

AstraZeneca has introduced digital health solutions into clinical trials, demonstrating improved patient experience, accelerated timelines and reduced costs.

Phase II trial results demonstrate rapid remission of macrophage activation syndrome in patients treated with the anti-IFNγ antibody emapalumab.